Medpace (MEDP) Lifted to Buy at ValuEngine
ValuEngine upgraded shares of Medpace (NASDAQ:MEDP) from a hold rating to a buy rating in a research note issued to investors on Thursday morning.
A number of other equities research analysts also recently weighed in on MEDP. BidaskClub raised shares of Medpace from a buy rating to a strong-buy rating in a research report on Wednesday, September 12th. SunTrust Banks started coverage on shares of Medpace in a report on Monday, September 17th. They issued a hold rating and a $63.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Medpace from a hold rating to a buy rating and set a $54.00 price objective for the company in a report on Thursday, November 1st. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Medpace has a consensus rating of Buy and a consensus price target of $44.43.
Shares of Medpace stock opened at $60.14 on Thursday. The stock has a market capitalization of $2.08 billion, a PE ratio of 39.57, a P/E/G ratio of 1.26 and a beta of 1.61. The company has a current ratio of 0.66, a quick ratio of 0.66 and a debt-to-equity ratio of 0.25. Medpace has a 1 year low of $31.75 and a 1 year high of $65.09.
Several institutional investors have recently bought and sold shares of MEDP. Vanguard Group Inc boosted its holdings in shares of Medpace by 63.6% in the third quarter. Vanguard Group Inc now owns 2,897,702 shares of the company’s stock valued at $173,601,000 after acquiring an additional 1,126,649 shares in the last quarter. Vanguard Group Inc. lifted its stake in Medpace by 63.6% during the third quarter. Vanguard Group Inc. now owns 2,897,702 shares of the company’s stock valued at $173,601,000 after purchasing an additional 1,126,649 shares during the last quarter. BlackRock Inc. lifted its stake in Medpace by 42.1% during the third quarter. BlackRock Inc. now owns 2,282,063 shares of the company’s stock valued at $136,719,000 after purchasing an additional 676,396 shares during the last quarter. Fuller & Thaler Asset Management Inc. acquired a new stake in Medpace during the third quarter valued at approximately $37,292,000. Finally, Renaissance Technologies LLC lifted its stake in Medpace by 131.6% during the third quarter. Renaissance Technologies LLC now owns 784,900 shares of the company’s stock valued at $47,023,000 after purchasing an additional 446,000 shares during the last quarter. Institutional investors and hedge funds own 67.54% of the company’s stock.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
See Also: What is a put option?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.